Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
about
Targeted Therapy in Biliary Tract CancersTargeted therapy in advanced bladder cancer: what have we learned?Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patientsMultiple mechanisms mediate resistance to sorafenib in urothelial cancerRisk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewThe role of genomics in the management of advanced bladder cancer.Targeting the VEGF pathway in metastatic bladder cancer.New advances in genitourinary cancer: evidence gathered in 2014.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Incorporating VEGF-targeted therapy in advanced urothelial cancer.Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.An Updated Review on Marine Anticancer Compounds: The Use of Virtual Screening for the Discovery of Small-Molecule Cancer Drugs.Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.A critical review on ramucirumab in the treatment of advanced urothelial cancer.Epigenetic Treatment Options in Urothelial Carcinoma.Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
P2860
Q26798443-B420741A-8142-44A3-9862-F81AAA1AE14AQ27009469-4C3CCD1C-E078-49E2-B686-B4FB73E579C4Q28079328-4838E40A-ABEC-479E-B895-C458E43F57F7Q34685436-E190D634-44EA-49FF-8092-70EA2D392F8DQ35691234-F74B6B6D-B229-4B91-80EC-CC356CA56603Q35998718-E2619972-1D36-4E02-B91B-E7AC98F58861Q36270115-BCEC1121-F95B-4A9D-ADA1-C1FDADCA85C3Q38342992-A4DA2600-D813-4630-8957-1624774E8B09Q38534167-FF69B3BB-D5E8-46DA-9AC0-180CB1ED64D5Q38557894-91CC1294-2F85-4BF7-B059-DF3751BC34CDQ38701535-F8EDD85C-E3FB-4053-9016-6637E6E9BBBBQ38753358-24EF5167-6F62-4D6E-8D0E-CA4F9C658B52Q38756931-2CF54160-C5D2-4D09-A310-3A92EB5FFD7AQ38876486-358C4FC1-3DDC-4A3E-9B44-84A390A70477Q39394159-AA802983-A29E-4417-BC11-2635F879D013Q41770394-57F4921B-68ED-4842-996F-77A5465CC3AEQ47787312-E8D580A2-043A-4338-B606-B19AA89603E1Q50182584-BD558A3B-8EC7-4B81-82F1-D463D69E155DQ53259976-2FCEF83A-0BBB-4E84-AE0D-2E4E351BFAC6
P2860
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)
@en
Prospective randomized double- ...... asized urothelial cancer: SUSE
@nl
type
label
Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)
@en
Prospective randomized double- ...... asized urothelial cancer: SUSE
@nl
prefLabel
Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)
@en
Prospective randomized double- ...... asized urothelial cancer: SUSE
@nl
P2093
P2860
P356
P1433
P1476
Prospective randomized double- ...... al cancer: SUSE (AUO-AB 31/05)
@en
P2093
Axel Heidenreich
Christian Wülfing
Frank vom Dorp
Hans Heinzer
Heidrun Rexer
Jan Roigas
Joern Kamradt
Margitte Retz
Mark Schrader
Michael Kühn
P2860
P304
P356
10.1111/BJU.12437
P577
2014-03-01T00:00:00Z